Key result
ESRD patients treated with CAPD had significantly higher serum levels of nitric oxide compared to healthy controls (19.09 vs 9.5; p<0.05), with no significant difference in endothelin-1.
Why the study?
Are serum levels of nitric oxide and endothelin-1 altered in ESRD patients treated with continuous ambulatory peritoneal dialysis compared to healthy controls?
Case-Control (n=53)
Are serum levels of nitric oxide and endothelin-1 altered in ESRD patients treated with continuous ambulatory peritoneal dialysis compared to healthy controls?
Absolute Event Rate: 19.09% vs 9.5%
p-value: p=< 0.05
ESRD patients on CAPD exhibit an imbalance in vasoactive substances, specifically elevated nitric oxide levels, which may contribute to hemodynamic disturbances and atherosclerosis.
No takes yet. Share an insight, caveat, or question.
NO/ET-1 levels in CAPD patients may signal endothelial changes; leaves open prognostic or therapeutic relevance pending prospective data.
Kovačević et al. (2013) conducted a case-control in End-stage renal disease (ESRD) (n=53). Continuous ambulatory peritoneal dialysis (CAPD) vs. Healthy controls was evaluated on Serum levels of nitric oxide (NO) (p=< 0.05). ESRD patients treated with CAPD had significantly higher serum levels of nitric oxide compared to healthy controls (19.09 vs 9.5; p<0.05), with no significant difference in endothelin-1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: